The mechanism and risk factors for immune checkpoint inhibitor pneumonitis in non-small cell lung cancer patients

The mechanism and risk factors for immune checkpoint inhibitor pneumonitis in non-small cell lung cancer patients

Immune checkpoint inhibitors (ICIs) are new and promising therapeutic agents for non-small cell lung cancer (NSCLC). However, along with demonstrating remarkable efficacy, ICIs can also trigger immune-related adverse events. Checkpoint inhibitor pneumonitis (CIP) has been reported to have a morbidit...

Full description

Bibliographic Details
Main Authors: Xiaoyang Zhai, Jian Zhang, Yaru Tian, Ji Li, Wang Jing, Hongbo Guo, Hui Zhu
Format: Article
Language:English
Published: China Anti-Cancer Association 2020-08-01
Series:Cancer Biology & Medicine
Subjects:
immune checkpoint inhibitor
non-small-cell lung cancer
pneumonitis
risk factors
Online Access:http://www.cancerbiomed.org/index.php/cocr/article/view/1668

Internet

http://www.cancerbiomed.org/index.php/cocr/article/view/1668

Similar Items